Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials

INTRODUCTION: Despite the fact that people older than 65 years of age have the highest incidence of developing breast cancer, these patients are excluded from clinical trials in most cases. Furthermore, most physicians tend towards therapy regimens without the use of dose-dense, highly active taxane...

Descripción completa

Detalles Bibliográficos
Autores principales: Loibl, Sibylle, von Minckwitz, Gunter, Harbeck, Nadia, Janni, Wolfgang, Elling, Dirk, Kaufmann, Manfred, Eggemann, Holm, Nekljudova, Valentina, Sommer, Harald, Kiechle, Marion, Kümmel, Sherko
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614510/
https://www.ncbi.nlm.nih.gov/pubmed/18796139
http://dx.doi.org/10.1186/bcr2144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614510/
https://www.ncbi.nlm.nih.gov/pubmed/18796139
http://dx.doi.org/10.1186/bcr2144

Ejemplares similares